GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ImmuPharma PLC (AQSE:IMM.GB) » Definitions » Net Margin %

ImmuPharma (AQSE:IMM.GB) Net Margin % : 0.00% (As of Jun. 2024)


View and export this data going back to 2016. Start your Free Trial

What is ImmuPharma Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. ImmuPharma's Net Income for the six months ended in Jun. 2024 was £-0.39 Mil. ImmuPharma's Revenue for the six months ended in Jun. 2024 was £0.00 Mil. Therefore, ImmuPharma's net margin for the quarter that ended in Jun. 2024 was 0.00%.

The historical rank and industry rank for ImmuPharma's Net Margin % or its related term are showing as below:

AQSE:IMM.GB' s Net Margin % Range Over the Past 10 Years
Min: -8897.53   Med: -5264.6   Max: 3517.14
Current: 3517.14


AQSE:IMM.GB's Net Margin % is ranked better than
99.01% of 1013 companies
in the Biotechnology industry
Industry Median: -140.3 vs AQSE:IMM.GB: 3517.14

ImmuPharma Net Margin % Historical Data

The historical data trend for ImmuPharma's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ImmuPharma Net Margin % Chart

ImmuPharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -7,851.28 -5,401.57 -6,927.12 - -

ImmuPharma Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - -1,210.00 2,962.86 -

Competitive Comparison of ImmuPharma's Net Margin %

For the Biotechnology subindustry, ImmuPharma's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ImmuPharma's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ImmuPharma's Net Margin % distribution charts can be found below:

* The bar in red indicates where ImmuPharma's Net Margin % falls into.



ImmuPharma Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

ImmuPharma's Net Margin for the fiscal year that ended in Dec. 2023 is calculated as

Net Margin=Net Income (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-2.922/0
= %

ImmuPharma's Net Margin for the quarter that ended in Jun. 2024 is calculated as

Net Margin=Net Income (Q: Jun. 2024 )/Revenue (Q: Jun. 2024 )
=-0.388/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ImmuPharma  (AQSE:IMM.GB) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.


ImmuPharma Net Margin % Related Terms

Thank you for viewing the detailed overview of ImmuPharma's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


ImmuPharma Business Description

Traded in Other Exchanges
Address
One Bartholomew Close, London, GBR, EC1A 7BL
ImmuPharma PLC is a drug discovery and development company. The pipeline of the company includes novel peptide-based therapeutics within two therapy areas: autoimmunity & inflammation, and anti-infectives. The company's drug candidate is Lupuzor, which treats lupus, a life-threatening autoimmune disease.

ImmuPharma Headlines

No Headlines